Regarding endpoints, and this is probably why there isn’t significant institutional interest - the P2 trial only had 9 participants didn’t it? I ask genuinely because I might have bad intel. If that is correct, then there is a material risk of those results not being replicated over say 100/200 participants. Also adding in combination therapies etc further adds to the risk. We are not over the finish line yet, but definitely showing real promise.
Chart, page-3851
-
- There are more pages in this discussion • 2,055 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
